Trigeminal Neuropathy.
Veerapaneni KD, Kapoor N, Veerapaneni P, Lui F, Nalleballe K.
2024 Mar 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A.
J Clin Oncol. 2010 Dec 10;28(35):5132-9. doi: 10.1200/JCO.2010.29.7101. Epub 2010 Nov 8.
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR Jr, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL.
JAMA. 2017 Jan 3;317(1):48-58. doi: 10.1001/jama.2016.19425.
Pathology of osteosarcoma.
Dahlin DC.
Clin Orthop Relat Res. 1975 Sep;(111):23-32. doi: 10.1097/00003086-197509000-00004.
Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer.
Irelli A, Cocciolone V, Cannita K, Zugaro L, Di Staso M, Lanfiuti Baldi P, Paradisi S, Sidoni T, Ricevuto E, Ficorella C.
Bone. 2016 Jun;87:169-75. doi: 10.1016/j.bone.2016.04.006. Epub 2016 Apr 26.
New developments for treatment and prevention of bone metastases.
Body JJ.
Curr Opin Oncol. 2011 Jul;23(4):338-42. doi: 10.1097/CCO.0b013e328347918b.
Clinical, histopathologic, subtype, and immunohistochemical analysis of jaw phosphaturic mesenchymal tumors.
Li D, Zhu R, Zhou L, Zhong D.
Medicine (Baltimore). 2020 Feb;99(7):e19090. doi: 10.1097/MD.0000000000019090.
Gorlin-Goltz syndrome--a medical condition requiring a multidisciplinary approach.
Kiwilsza M, Sporniak-Tutak K.
Med Sci Monit. 2012 Sep;18(9):RA145-53. doi: 10.12659/msm.883341.
A cartilage-forming tumor of the mandibular angle: a case report.
Ismail A, Boujguenna I, Hattab K, Mansouri N, El Ganouni NCI, Idrissi MO, Hazmiri FE, Rais H.
J Med Case Rep. 2022 Apr 28;16(1):176. doi: 10.1186/s13256-022-03359-x.
The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma (Review).
Jimi E, Shin M, Furuta H, Tada Y, Kusukawa J.
Int J Oncol. 2013 Mar;42(3):803-9. doi: 10.3892/ijo.2013.1794. Epub 2013 Jan 23.
